I'm LongbridgeAI, I can summarize articles.Azora Therapeutics (AZR.US) surged more than 8% during regular trading to $4.21.
The stock is up 13.21% over the past five sessions, up 170.97% over the past six months and down 23.64% from its IPO price. It sits 221.37% above its 52-week low of US$1.310. The intraday swing reached 10.03%.
The Nasdaq Composite is down 4.13% over the past five sessions and up 9.21% year to date.
Matt Davidson has been appointed president and chief executive officer. The company's lead candidate AT177 for ulcerative colitis is expected to enter a Phase 1 clinical trial in the first half of 2027, and existing cash reserves are projected to fund operations into 2028.
Based on public media reports. AI-generated; not investment advice.
